灵芪蠲肝合剂治疗慢性乙肝肝纤维化的临床观察

Clinical Observation on Liver Fibrosis of Chronic Hepatitis B Treated with Linqijuangan-Mixture

目的观察灵芪蠲肝合剂在治疗慢性乙肝中抗肝纤维化的临床疗效及作用机理。方法将46例慢性乙肝肝纤维化患者随机分为灵芪蠲肝合剂治疗组24例和对照组22例,观察临床疗效及治疗前、治疗2个月后患者的肝功能(ALT、AST、TBIL)、血清肝纤维化指标(HA、LN、PCⅢ、Ⅳ-C))及抗氧化指标(SOD、GSH-PX、MDA)水平变化,并作对比分析。结果经治疗后,两组患者临床疗效及肝功能较治疗前均有明显好转(P<0.05);治疗组患者血清肝纤维化指标、MDA均较治疗前明显降低,SOD、GSH-PX均明显上升(P<0.05)。与对照组比,治疗组ALT、AST、TBIL、LN、PCⅢ、Ⅳ-C、MDA降低明显(P<0.05),SOD、GSH-PX增加明显(P<0.05);而HA降低无显著性差异。结论灵芪蠲肝合剂通过调节抗氧化和脂质过氧化而对慢性乙肝有一定的抗肝纤维化作用。

Objective To investigate the clinical effect and mechanism of linqijuangan-Mixture on anti--fibro- sis during the treatment with chronic hepatitis B. Methods 46 cases of chronic fibrosis of liver were randomly di- vided into Linqijuanganye treatment group （24 cases） and control group （22 cases）. Clinical effects, liver function, serum indexes of liver fibrosis and antioxidant were determined and analysed before treatment and after treatment for 2 months. Results After two month＇s treatment, the clinical effects and liver function in both groups were significantly improved （P〈O. 05）. The levels of serum liver fibrosis indexes and MDA decreased significantly, SOD and GSH-PX increased significantly after treatment as compared with those before treatment in treatment group （P 〈0.05）. And in the treatment group the levels of ALT, AST, TBIL, LN, PCⅢ, Ⅳ-C, MDA were decreased, SOD, GSH-PX increased more significantly than those in the control group （P〈O. 05） , while the change of HA had no significant difference. Conclusions Linqijuangan-Mixture has satisfactory actions of anti-Lioex fibrosis in the treatment of chronic hepatitis B through regulation of the anti-oxidant system and lipid peroxidation.